NICE Expands Drug Access for Young Children With NF1 Tumours Edited by Zeel Mehta

https://www.medscape.com/viewarticle/nice-expands-drug-access-young-children-nf1-tumours-2026a1000x4h?src= The National Institute for Health and Care Excellence (NICE) has recommended mirdametinib (Ezmekly, Merck Serono) as an option for children and young people aged 2-17 years with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1 (NF1). Around 200 patients are expected to benefit.